Aravive (STU:VE11) Dividends per Share : €0.00 (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Aravive Dividends per Share?

Aravive's dividends per share for the three months ended in Sep. 2023 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, Aravive's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Aravive Dividends per Share Historical Data

The historical data trend for Aravive's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Dividends per Share Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividends per Share

Get a 7-Day Free Trial

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aravive's Dividends per Share

For the Biotechnology subindustry, Aravive's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aravive's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Aravive's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Aravive Dividends per Share Calculation

Dividends paid to per common share.

Aravive (STU:VE11) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Aravive's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	Earnings per Share (Diluted) (Q: Sep. 2023 )
	=	0	/	0.262
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Aravive Dividends per Share Related Terms

Thank you for viewing the detailed overview of Aravive's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive Headlines

No Headlines